OBJECTIVE: To validate a variation of a well-established magnetic resonance imaging (MRI) technique to detect liver fat and use it to monitor liver fat changes after treatment with dexfen¯uramine in men with non-insulin dependent diabetes mellitus (NIDDM). DESIGN: (a) Simple correlation study of MRI Liver Fat Index with liver biopsy results; (b) Open Study of 10 men with NIDDM treated with dexfen¯uramine for 12 weeks in addition to their`usual' therapy. SUBJECTS: (a) 19 patients (3F; 16M) with abnormal liver function tests undergoing liver biopsy; (b) 10 men, Body Mass Index (BMI)`30, Waist to hip ratio (WHR) b0.90 with poorly controlled NIDDM despite oral sulphonylurea therapy. MEASUREMENTS: (a) MRI liver fat; standard liver biopsy; (b) MRI visceral fat, MRI liver fat, euglycaemic clamp, plasma lipids, fasting glucose and c-peptide levels. RESULTS: In the validation group, there was a strong relationship between the MRI Liver Fat Index and histopathological assessment of the liver biopsies (r 0.87,`0.0001). During treatment with dexfen¯uramine the mean Liver Fat Index reduced from 10.6 AE 3.4 to 6.6 AE 2.8 (P 0.05). The reduction in Liver Fat Index correlated with the reduction in visceral fat (r 0.84, P 0.001) as well as with the improvement in insulin sensitivity (r 0.62, P 0.05). Using partial correlation analysis, the relationship between the change in visceral adipose tissue and the improvement in insulin sensitivity was weaker if the Liver Fat Index was kept constant (r 0.76 decreased to r 0.56). CONCLUSIONS: In this group of subjects MRI Liver Fat Index correlated well with liver fat as seen on biopsy. The Liver Fat Index reduced after 12 weeks therapy with dexfen¯uramine suggesting a role for hepatic steatosis in the complex interaction between visceral adipose tissue and insulin sensitivity.
Introduction
There are many studies using either computed tomography (CT) or magnetic resonance imaging (MRI) which look at the complex interaction between visceral adipose tissue and metabolic parameters. 1±4 The liver is thought to contribute to peripheral insulin resistance by reducing insulin clearance when subjected to an increased portal non-esteri®ed fatty acid (NEFA)¯ux. 5, 6 Increased liver fat thus results in increased peripheral insulin levels, leading to a down regulation of insulin receptors and subsequently decreased glucose uptake. It is this condition which is known as insulin resistance. 7 Despite this interaction between visceral adipose tissue, insulin sensitivity and liver fat, few studies have attempted to document hepatic steatosis.
The diagnosis of fatty liver has traditionally relied on histological evidence from liver biopsy. Although biochemical tests of liver function, 8 ultrasound, 9 computed tomography 10 and even 133 Xenon clearance rates 11 have been used, none of these techniques have proven to be speci®c for fatty liver 12, 13 nor sensitive enough to grade hepatic steatosis. Conventional magnetic resonance imaging using spin-echo techniques is insensitive in detecting fatty in®ltration of the liver. 14 Although proton chemical shift imaging methods as described by Dixon in 1984 make it possible to grade fatty liver, 15, 16 this technique unfortunately requires speci®c software which is not readily available.
Magnetic resonance spectroscopy has however been shown to be as good as CT-evaluated fat ratios. 17 Technical dif®culties associated with spectroscopy methods in patients with large amounts of either omental or visceral fat have been documented and preclude this method for patients with abdominal obesity. 18 In addition, spectroscopy is unable to detect fat in a normal liver and as this is thought to comprise up to 5% of the total liver by weight, 19 more sensitive methods are needed to enable small changes to be seen.
To enable liver fat to be measured concurrent with visceral adipose tissue we applied a new variation of an established pre-spectral technique using water suppression rather than fat suppression to develop a number comparison relative to adjoining subcutaneous fat as described below. This method was then validated against liver histology in subjects scheduled for liver biopsy.
In the application of this technique, 10 men with NIDDM who had a WHR b0.90 suggesting increased visceral adipose tissue underwent MRI at week 0 and week 12. In between they were treated with dexfenuramine 15 mg b.i.d. in addition to their usual diabetic medication. Liver biopsy was not performed on this group of patients as liver function tests showed no abnormality and clinically there was no evidence of hepatic enlargement. Subjects showed a signi®cant 32% reduction in visceral fat area after 12 weeks together with an improvement in insulin sensitivity. This study has been described in detail elsewhere. 20 By measuring the Liver Fat Index we aimed to assess the interaction between visceral adipose tissue, liver fat and insulin sensitivity in men with NIDDM and an abdominal fat distribution.
Methods

Development and validation of MRI liver fat index
Patients Nineteen patients who were to undergo liver biopsy because of abnormal liver function tests were recruited from the Gastroenterology Department at the John Radcliffe Hospital, Oxford, UK. There were 3 females and 16 males with an age range of 23± 60 (mean 47 y). All patients gave a history of alcohol consumption ranging from 10±20 gms alcohol/d. Various abnormalities on liver function tests were seen including elevated transaminase and gamma-GT levels. Patients with liver function tests suggestive of obstruction such as isolated elevation of alkaline phosphatase levels were included only after ultrasound examination showed no evidence of dilated intra or extra-hepatic ducts. MRI was performed immediately prior to the liver biopsy provided that the subject's consent was obtained. The study was approved by the ethics committee at the John Radcliffe Hospital, Oxford.
MRI All magnetic resonance imaging (MRI) studies were performed on a Sigma Advantage machine (General Electric, Milwaukee, USA) operating at 1.5 Tesla. The patients were examined in the supine position and all images were obtained using the radio frequency (RF) coil. A series of four spin echo T1 weighted transverse sections were obtained through the liver to include both right and left lobes. Shimming was not used for these images. The parameters for the transverse series were: repetition time (TR) 300 ms, time to echo (TE) 12 ms, 256 6 128 matrix, 4 excitations (NEX), ®eld of view 40 cm, slice thickness 10 mm, inter slice gap 10 mm.
Additional software options selected were respiratory compensation (Exorcist 2, 21 and superior and inferior pre-saturation pulses to reduce respiratory motion and blood¯ow artifact respectively). 22 Total sequence time for the transverse series was 2 min 34 s. The water component of the MR signal was suppressed by the`spectral presaturation' technique similar to that used for fat suppression. 23 Each patient study was completed within 15 min.
The signal intensity of liver was measured by placing an operator de®ned region of interest (ROI) over the periphery of the lateral aspect of the right lobe of liver approximately in the mid-clavicular line. This was chosen to be close to the anticipated site of the biopsy (Photo 1). The ROI was positioned to avoid hepatic or portal vessels and was made as large as feasible. To correct for signal originating from high intensity subcutaneous fat a ROI of equivalent size to that placed over the liver was positioned outside the patient along the same phase encoding lines. The signal intensity of the background noise was measured and this was subtracted from the liver signal intensity. In order to correct for differences in the gain settings of the transmit and receive ampli®ers, given that the settings were optimised for each sequence on each patient, a ROI was placed over the subcutaneous fat of the thoracic wall immediately lateral to the liver ROI also avoiding blood vessels. The signal intensity of the liver was calculated as a percentage of the intensity of subcutaneous fat. All scans were analysed by a single observer (NM) and the co-ef®cient of variation for the Liver Fat Index was measured as 4.7%.
Liver biopsy Liver biopsies were obtained by the standard Menghini technique and were sectioned and stained with haematoxylin and eosin. An independent histopathologist who was unaware of the MRI results graded the specimens in relation to fatty change as normal' or`mild/moderate/severe' fatty change as in normal clinical practice. Fat vacuoles or macrovesicles (the fat dissolves out during processing leaving a vacuole) were also counted manually over 40 adjacent high power ®elds (Â400 magni®cation) and expressed as fat vacuoles per high power ®eld (f/hpf) (see Photo 2) . Comparison of the two grouping methods showed those assessed as normal to have`1 f/hpf. Those with`mild fatty change' had 1±19 f/hpf, those with moderate fatty change' had 20±50 f/hpf, while those with`severe fatty change' had b50 f/hpf.
Liver biopsies frozen at 70 C were thawed and weighed. The triacylglycerol (TAG) was then extracted from the homogenised sample with 2:1 (v/v) chloroform/methanol. 24 After the addition of 1 ml of 4 mmol/l magnesium chloride the samples were spun to separate the organic layer, this was dried down under nitrogen. The TAG was then measured using a modi®ed kit method (Triglyceride Merckotest 14354 Merck Ltd Poole UK. 25 
Methods
Clinical study in abdominally obese men with NIDDM Patients and methods In this study 10 men with NIDDM and an abdominal distribution of body fat were given 15 mg dexfen¯uramine b.i.d. in addition to their usual diabetic medication.
Inclusion criteria included BMI`30, WHR b 0.9 and age 40±70 y. Diet records over a 7 d period were analysed before and after the intervention and showed a reduction in total fat intake. Visceral fat area on MRI was measured using a technique described elsewhere 19 and was seen to reduce over the 12 week treatment period. Subcutaneous fat did not signi®-cantly change. Metabolic indices including insulin sensitivity assessed by euglycaemic glucose clamp as well as serum cholesterol, triglyceride, free fatty acids, C-peptide, glucose and glycated haemoglobin were measured over this time.
These subjects underwent liver fat assessment using MRI but did not have a liver biopsy as liver function tests were normal. The liver fat assessment was performed at the same time as the MRI assessment of abdominal fat and did not add more than 10 min to the scanning time.
Statistics
(a) Validation study: Descriptive results are expressed as mean AE standard deviation. The Liver Fat Index (from MRI) was correlated with fat globules/hpf, using Pearson's correlation and a regression line was ®tted to the data. Triglyceride content (nmol/mg) and histological grading using Spearman's rank correlation was also related to the Liver Fat Index. (b) Clinical study (i) The relationships between the Liver Fat Index and insulin sensitivity, insulin sensitivity and visceral fat, and visceral fat and the Liver Fat Index were correlated by non-parametric Spearman's rank. (ii) The effect of controlling for liver fat, to assess the relationship between visceral fat and insulin sensitivity was assessed by partial correlation analysis using Kendall's P.
Results
Validation study Liver biopsy: In the 19 specimens obtained for histopathological analysis, fat globules per high power ®eld (f/hpf ) ranged from`1 up to 119 (see Figure 1) . Eight patients were classi®ed as normal, six had mild, three had moderate and two had severe fatty change as seen on microscopy. Patients also had a variety of other histopathological diagnoses including cirrhosis and hepatitis. Using Pearson's correlation, the Liver Fat Index correlated strongly with the number of fat globules/ hpf seen on biopsy (r 0.87, P`0.001, Figure 1 ) as well as with that analysed biochemically (Spearman's r 0.63, P 0.006). When liver biopsies were graded between 1 for normal liver up to 4 for severe fatty in®ltration there was also a strong correlation with the Liver Fat Index fat measured on MRI (Spearman's r 0.91, P`0.001).
Clinical study The selective reduction in visceral adipose tissue area, improvement in metabolic indices and reduction in dietary fat intake have been discussed in detail previously. 20 The Liver Fat Index representing the ratio of liver fat to subcutaneous fat ranged from 3.3±19.2 and showed a reduction from a mean of 10.6 AE 3.4±6.6 AE 2.8 over the 12 weeks on dexfen¯ur-amine ( Figure 2 ). Mean body weight reduced by only 3 kg and the reduction in body weight did not correlate with reduction in either visceral adipose tissue nor with change in the Liver Fat Index.
The Liver Fat Index at baseline correlated signi®-cantly (r 0.79, P 0.002) with the baseline visceral adipose tissue area. After 12 weeks on dexfen¯ura-mine the reduction in Liver Fat Index was signi®-cantly associated with the reduction in visceral adipose tissue area (r 0.84, P 0.001) but not with indices of glycaemic control nor with changes in body weight. Insulin sensitivity (S 1 clamp) improved over the study period (0.29 AE 0. 13 ) (P 0.002)]. Other metabolic changes seen included a signi®cant reduction in plasma total cholesterol (P`0.001) and triglyceride levels (P 0.02) and Cpeptide (P 0.002). Fasting glucose levels were unchanged. The correlation coef®cient between the reduction in visceral adipose tissue and the improvement in insulin sensitivity fell from r 0.76 to r 0.56 after taking the reduction of the Liver Fat Index into account on partial correlation suggesting that change in the Liver Fat Index mediated the improved insulin sensitivity subsequent upon reduction in visceral adipose tissue.
Discussion
Himsworth in 1936 was the ®rst to differentiate between insulin sensitive and insulin insensitive diabetes mellitus. 26 The latter was seen in conjunction with fatty liver which was thought to contribute to the elevated blood glucose levels by increasing glucose production. A clinical association between levels of insulin sensitivity and hepatic steatosis measured by ultrasound techniques has been described in patients with hypertension who are either alcohol consumers or obese people or both, 27 while an acute improvement in insulin sensitivity following alcohol withdrawal was demonstrated by Adner and Nygren 28 in 1990. These studies suggest that there are similar metabolic consequences following fatty liver due to alcohol abuse as those seen with either diabetes or obesity.
The waist to hip ratio (WHR) as an indicator of visceral adipose tissue accounts for a large proportion of the variance in liver fat irrespective of weight, BMI or % body fat 29 suggesting that the liver fat is dependent on the amount of visceral adipose tissue. More recently, liver fat measured by CT scanning has been shown to be associated with levels of visceral adipose tissue volume and serum triglycerides 7 while other studies have shown an association between fatty liver, decreased insulin clearance and insulin resistance. 30 To our knowledge, no previous work has shown a change in liver fat associated with a reduction in visceral adipose tissue and improvement in insulin sensitivity.
While liver biopsy remains the`gold standard' for diagnosis and grading of fatty change, it is not always feasible if the clotting pro®le is abnormal or if repeat investigations are required. For patients with essentially normal liver function and no clinical signs of liver disease it is too invasive for the likely bene®t. Many patients with mild abnormalities on biochemical tests are labeled as`fatty liver' without any de®nitive diagnostic procedure.
Previous estimates of liver fat have suggested that a normal liver is approximately 5% fat 19 while the normal triglyceride content has been measured at % 8.6 mg/g in rats 31 and % 5 mg/g in humans. 32 In fatty liver, these values increased to 42.7 mg/g and 247 mg/g respectively. The values detailed in our study were comparable and ranged from 3.25 nmol/ mg up to 48.1 nmol/mg wet weight. Our patients with normal liver histology had a Liver Fat Index of`10 suggesting that liver fat content is usually less than 10% when compared to the adjacent subcutaneous fat value. This value must not be confused with other methods of detecting fat on MRI such as the Dixon technique where values of`7% in normal liver and between 13±64% have been documented for fatty liver. 33 Although the Dixon method may have some advantages our study is simpler to perform and histological correlation indicates that it is robust in the clinical area.
Our technique allows a single measure of liver fat similar to that obtained from liver biopsy. Inevitably there were some variations in signal intensity across the water suppressed image. Minor changes were sometimes seen corresponding to the elements of the quadrature body coil but the anterior, posterior, right and left lateral parts of the images were relatively immune to signal shading. It was partly for this reason that regions of interest were taken in the periphery of the right lobe of the liver (avoiding all detectable vessels) and the immediately adjacent subcutaneous fat (also avoiding blood vessels). It is not attempting to measure absolute fat content of the liver as the value obtained applies only to the small area of the liver over which the region of interest (ROI) was applied.
We were able to grade hepatic fat and detect low levels. The results showed good correlation with liver biopsy suggesting that this technique is of bene®t in patients requiring documentation of fatty liver. It does not differentiate between simple fat in®ltration and fatty changes seen with either hepatitis or cirrhosis but is able to detect changes in liver fat occurring after a simple intervention as seen in our 10 patients after treatment with dexfen¯uramine. The open design of that study does not allow a conclusion to be drawn as to the relative contribution of reduced fat intake, improved insulin sensitivity or direct drug effect on the reduction in Liver Fat Index.
Conclusions
This study, ®rstly demonstrating a new application of an established MRI technique to assess liver fat and subsequently using the method to monitor changes in liver fat induced by dexfen¯uramine, adds further weight to the concept of hepatic steatosis contributing to the metabolic derangement seen in patients with large amounts of visceral adipose tissue. The interdependence of the relationship between insulin sensitivity, visceral fat and liver fat needs further investigation although the results of this early work suggests that fatty liver could be added to the increasing list of features of the`Metabolic Syndrome' previously known as`Syndrome X' as described by Reaven. 34 Dexfen¯uramine in this open study was associated with a reduced Liver Fat Index in addition to its previously reported ability to preferentially reduce visceral adipose tissue more than subcutaneous adipose tissue 20 and hence holds promise as adjunct therapy in the`Metabolic Syndrome'.
